Marvin E. Jaffe
Direttore/Membro del Consiglio presso Matrix Pharmaceuticals, Inc.
Profilo
Marvin E.
Jaffe is currently a Director at Matrix Pharmaceuticals, Inc. and a Partner at Naimark & Associates PC.
He previously served as a Director at Immunomedics, Inc., NeoGenomics, Inc., Allos Therapeutics, Inc., Celltech Group Plc, Genta, Inc., Genetic Therapy, Inc., Vernalis Group Plc, Merck & Co., Inc., Organon Pharma (UK) Ltd., and as the Founding President of R.W.
Johnson Pharmaceutical Research Institute.
Dr. Jaffe holds a doctorate degree from Thomas Jefferson University.
Posizioni attive di Marvin E. Jaffe
| Società | Posizione | Inizio |
|---|---|---|
| Matrix Pharmaceuticals, Inc. | Direttore/Membro del Consiglio | 05/04/2010 |
| Naimark & Associates PC | Corporate Officer/Principal | 05/04/2010 |
Precedenti posizioni note di Marvin E. Jaffe
| Società | Posizione | Fine |
|---|---|---|
| NEOGENOMICS, INC. | Direttore/Membro del Consiglio | 03/02/2011 |
| IMMUNOMEDICS, INC. | Direttore/Membro del Consiglio | 27/08/2009 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Direttore/Membro del Consiglio | 10/05/2006 |
| R.W. Johnson Pharmaceutical Research Institute | Presidente | 01/01/1994 |
Genta, Inc.
 Genta, Inc. Pharmaceuticals: MajorHealth Technology Genta, Inc. is in the process of bankruptcy. The company formerly engages in pharmaceutical research and development. Genta was founded on February 4, 1988 and is headquartered in Berkeley Heights, NJ. | Direttore/Membro del Consiglio | - |
Formazione di Marvin E. Jaffe
| Thomas Jefferson University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| NEOGENOMICS, INC. | Health Services |
| Aziende private | 10 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Genta, Inc.
Genta, Inc. Pharmaceuticals: MajorHealth Technology Genta, Inc. is in the process of bankruptcy. The company formerly engages in pharmaceutical research and development. Genta was founded on February 4, 1988 and is headquartered in Berkeley Heights, NJ. | Health Technology |
Genetic Therapy, Inc.
 Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Commercial Services |
Organon Pharma (UK) Ltd.
 Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Health Technology |
Vernalis Group Plc
 Vernalis Group Plc Pharmaceuticals: MajorHealth Technology Vernalis Group Plc a UK based company engages in research and development of pharmaceutical products.The current status of the company is extinct. | Health Technology |
| Naimark & Associates PC | |
| R.W. Johnson Pharmaceutical Research Institute | |
| Matrix Pharmaceuticals, Inc. |
- Borsa valori
- Insiders
- Marvin E. Jaffe
